Market Trends Merck ends development of two antibody programsBy admin8996erT0allDecember 17, 2024 JHVEPhoto/iStock Editorial via Getty Images Merck (NYSE:MRK) is ceasing development of two monoclonal antibody candidates it was eying as fixed-doses…
